| KUFOVA, Z., T. SEVCIKOVA, K. GROWKOVA, P. VOJTA, J. FILIPOVA, Zdeněk ADAM, Luděk POUR, Miroslav PENKA, R. RYSAVA, Pavel NĚMEC, Lucie BROŽOVÁ, Petra VYCHYTILOVÁ, A. JURCZYSZYN, S. GROSICKI, A. BARCHNICKA, M. HAJDUCH, M. SIMICEK a R. HAJEK. Biomarkers in immunoglobulin light chain amyloidosis. Klinická onkologie. Praha: Ambit Media, 2017, roč. 30, Suppl. 2, s. "2S60"-"2S67", 8 s. ISSN 0862-495X. Dostupné z: https://dx.doi.org/10.14735/amko20172S60. |
Další formáty:
BibTeX
LaTeX
RIS
@article{1395504,
author = {Kufova, Z. and Sevcikova, T. and Growkova, K. and Vojta, P. and Filipova, J. and Adam, Zdeněk and Pour, Luděk and Penka, Miroslav and Rysava, R. and Němec, Pavel and Brožová, Lucie and Vychytilová, Petra and Jurczyszyn, A. and Grosicki, S. and Barchnicka, A. and Hajduch, M. and Simicek, M. and Hajek, R.},
article_location = {Praha},
article_number = {Suppl. 2},
doi = {http://dx.doi.org/10.14735/amko20172S60},
keywords = {amyloidosis; genome; microRNA; plasma cell; transcriptome; immunoglobulin},
language = {eng},
issn = {0862-495X},
journal = {Klinická onkologie},
title = {Biomarkers in immunoglobulin light chain amyloidosis},
volume = {30},
year = {2017}
}
TY - JOUR
ID - 1395504
AU - Kufova, Z. - Sevcikova, T. - Growkova, K. - Vojta, P. - Filipova, J. - Adam, Zdeněk - Pour, Luděk - Penka, Miroslav - Rysava, R. - Němec, Pavel - Brožová, Lucie - Vychytilová, Petra - Jurczyszyn, A. - Grosicki, S. - Barchnicka, A. - Hajduch, M. - Simicek, M. - Hajek, R.
PY - 2017
TI - Biomarkers in immunoglobulin light chain amyloidosis
JF - Klinická onkologie
VL - 30
IS - Suppl. 2
SP - "2S60"-"2S67"
EP - "2S60"-"2S67"
PB - Ambit Media
SN - 0862495X
KW - amyloidosis
KW - genome
KW - microRNA
KW - plasma cell
KW - transcriptome
KW - immunoglobulin
N2 - Immunoglobulin light chain amyloidosis (AL amyloidosis - ALA) is a monoclonal gammopathy characterized by presence of aberrant plasma cells producing amyloidogenic immunoglobulin light chains. This leads to formation of amyloid fibrils in various organs and tissues, mainly in heart and kidney, and causes their dysfunction. As amyloid depositing in target organs is irreversible, there is a big effort to identify bio marker that could help to distinguish ALA from other monoclonal gammopathies in the early stages of disease, when amyloid deposits are not fatal yet. High throughput technologies bring new opportunities to modern cancer research as they enable to study disease within its complexity. Sophisticated methods such as next generation sequencing, gene expression profiling and circulating microRNA profiling are new approaches to study aberrant plasma cells from patients with light chain amyloidosis and related diseases. While generally known mutation in multiple myeloma patients (KRAS, NRAS, MYC, TP53) were not found in ALA, number of mutated genes is comparable. Transcriptome of ALA patients proves to be more similar to monoclonal gammopathy of undetermined significance patients, moreover level of circulating microRNA, that are known to correlate with heart damage, is increased in ALA patients, where heart damage in ALA typical symptom.
ER -
KUFOVA, Z., T. SEVCIKOVA, K. GROWKOVA, P. VOJTA, J. FILIPOVA, Zdeněk ADAM, Luděk POUR, Miroslav PENKA, R. RYSAVA, Pavel NĚMEC, Lucie BROŽOVÁ, Petra VYCHYTILOVÁ, A. JURCZYSZYN, S. GROSICKI, A. BARCHNICKA, M. HAJDUCH, M. SIMICEK a R. HAJEK. Biomarkers in immunoglobulin light chain amyloidosis. \textit{Klinická onkologie}. Praha: Ambit Media, 2017, roč.~30, Suppl. 2, s.~''2S60''-''2S67'', 8 s. ISSN~0862-495X. Dostupné z: https://dx.doi.org/10.14735/amko20172S60.
|
